• About Us
  • Board
  • Careers
  • Contact Us
  • Management
  • News & Press
  • People
• FCOI Policy
• Home
• InVitria Case Study
• Medicines
  • Infectious Disease
    • VEN BETA
  • Inflammatory Disease
    • VEN120
• Newsletter Signup
• Privacy Policy
• Site map
• Technology
  • BioShare
  • Evidence
  • ExpressTec
  • Partnerships
• Ventria Difference

Posts by category

• Category: In Context
  • CuraVive, the Next Generation Plant-Based Food Ingredients
  • Secretory IgA: potential new weapon against respiratory transmission of SARS-CoV-2?
  • Could IgA from Human Breast Milk Offer Insights into Potential Treatments for COVID-19?
  • Human Milk Proteins: Their Power to Improve the Health Status of Children in Developing Countries
  • Design and Objectives of the ELCIE Clinical Trial
  • Breastmilk and the developing infant brain
  • Studying a potential new insulin analog for diabetes therapy
  • Clinical study: can a protein derived from breastmilk palliate symptoms of inflammation in the elderly?
  • Ventria Bioscience partners with BMGF to address pediatric diarrhea in the developing world
  • Causes of diarrhea in children: The Global Enteric Multicenter Study (GEMS)
  • Protecting American scientific innovation for the greater good
  • Alleviating symptoms of pediatric diarrhea in developing countries
  • Mechanism of Action of rhLactoferrin in Inflammatory Bowel Disease (IBD)
  • Welcome to In Context
• Category: News - Press
  • Ventria Bioscience wins exclusion order against infringing and mislabled products from Wuhan Healthgen
  • Ventria Bioscience has doubled biomanufacturing capacity for cell culture products
  • Ventria Bioscience Inc. Scores Key Victory in Fight Against Infringing Chinese Recombinant Albumin
  • Ventria Bioscience’s ExpressTec Delivers the Power to Improve the Health Status of Children in Developing Countries
  • Biotech Manufacturing Trends from the Bioprocess International 2018 Conference
  • Digestive Disease Week
  • The Essential Protein Engineering Summit (PEGS)
  • Ventria Bioscience CEO interviewed on CNBC
  • Ventria Bioscience aids global fight against intestinal infections that threaten up to 400 million children a year
  • Ventria Bioscience will double biomanufacturing capacity for therapeutic proteins, reagents and cell culture products
  • Ventria Bioscience announces peer-reviewed publication on novel mechanism of action in inflammatory bowel disease
  • Ventria Wins Economic Development Award

Partners

• Bill & Melinda Gates Foundation
• Children’s Hospital Colorado and University of Colorado School of Medicine
• Johns Hopkins School of Medicine
• UC Davis
• University of Minnesota